Navigation Links
MiMedx Announces Record First Quarter 2013 Results
Date:5/1/2013

2012. The increase in the first quarter 2013 Net Loss as compared to the Net Loss in the first quarter of 2012 included a non-recurring non-cash charge of $1.3 million related to the acceleration of recorded financing expense associated with the debt discount. Excluding this one-time item, the Net Loss would have been approximately $292,000. Additionally, the Net Loss includes a total of $1.4M in non-cash related expenses including $985,000 in share based compensation expense, $263,000 in amortization of intangibles and $99,000 in depreciation expense. Research and development expenses in the first quarter of 2012 increased by $840,000 over the first quarter of 2012 expenses due to the accelerated investment in clinical trials for reimbursement purposes and patent related costs. Selling, general and administrative expenses for the first quarter increased by $5.7 million over first quarter of 2012 expenses due to the build out of the Company's direct sales force for government and commercial accounts , as well as the addition of key management and infrastructure related resources to support the Company's growth.

Use of non-GAAP Financial MeasuresManagement has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles (GAAP). These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted EBITDA* is earnings before interest, taxes, depreciation, amortization, share-based compensation, non-cash impairment and earnout liability charges. For a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure, see accompanying table to this release. Adjusted financia
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
2. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
3. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
4. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
5. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
6. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
7. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
10. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 18, 2014 Scientists at NYU Langone Medical ... the efficiency of the process for turning adult cells ... compounds, including vitamin C. Using the new technique in ... obtained from adult skin cells by more than 20-fold ... is efficient and reliable, and thus should generally accelerate ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... , September 19, 2014 ... technology, development of emerging drug systems and advanced Laboratory ... Dickinson and Company (NYSE: BDX ), Thermo ... Biosciences Inc. (NASDAQ: RGDO ), Sangamo Biosciences ... (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Pfenex to Present at Upcoming Industry Conference on September 26 2
... ARAY ), a global leader in ... official journal of the Congress of Neurological,Surgeons, has ... , The supplement, titled ... different countries, focused on brain and spine,treatment using ...
... Inc. (ERT), (Nasdaq: ERES ), ... to provide integrated Cardiac Safety and Ambulatory ... to clinical trial sponsors and managers worldwide.eResearchTechnology ... (ECG), eClinical technology, ePRO, and other services ...
... Cell Technologies, Inc., a leader in adult stem cell production, announced ... Dr. Bayer will be responsible for developing pre-clinical and clinical ... trials using Stemedica products. , ... San Diego, CA ...
Cached Biology Technology:Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience 2Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience 3Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience 4ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 2ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 3ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 4Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 2Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 3
(Date:9/19/2014)... for the sake of fairness per se but in ... say Frans de Waal, PhD, and Sarah Brosnan, PhD, ... which is defined as a negative reaction to unequal ... , Their conclusion comes after the co-authors reviewed ... that it is the evolution of forestalling partner dissatisfaction ...
(Date:9/18/2014)... PULLMAN, Wash. - Washington State University researchers have developed ... sediment to power waste cleanup in rural areas. ... lead to an inexpensive and quick way to clean ... treatment plants while reducing pollution. , Professor Haluk ... College of Engineering and Architecture discuss the system in ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2
... fuel sources are lighting a fire under research to turn ... Bill 20, signed this week by Gov. Rick Perry, compliments ... used. The new law requires more renewable energy to be ... consumer energy needs and agriculture industry trends with the legislation ...
... some day be defeated by a single treatment, according ... University of Georgia's College of Veterinary Medicine. , Their ... and Marburg and includes investigators from Vanderbilt University Medical ... The study is being funded by a grant from ...
... Berkeley, has found that damage to a cell's DNA sets ... of a marker recognized by the body's immune system. , ... advanced online issue of Nature, shed light on a long-standing ... are able to attack tumors - can differentiate cells that ...
Cached Biology News:Researchers find ways to turn manure into power 2Researchers find ways to turn manure into power 3Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases 2New study finds how cells with damaged DNA alert the immune system 2New study finds how cells with damaged DNA alert the immune system 3
... Polymerase I Large (Klenow) Fragment, Exonuclease Minus, ... both the 5´→3´ and the 3´→5´ exonuclease ... Polymerase I (1,2). It is used for ... displacement amplification (5). Klenow Fragment, Exonuclease Minus, ...
Goat polyclonal to Duffy / FY / DARC...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
... fully licensed, high throughput, water bath thermal cycler ... 24 microplates. This equates to 9,216 reactions per ... robotic arm rapidly transfers a basket of plates ... times that are considerably faster than those of ...
Biology Products: